BridgeBio preps approval push after dwarfism drug increases children's height in phase 3
Fuente:
FierceBiotech
BridgeBio is hoping that infigratinib will get another shot at approval after the medicine hit the key goals of a phase 3 study in a form of dwarfism in children.